Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Biomx Inc PHGE

Healthcare Biotechnology
BiomX Inc., formerly Chardan Healthcare Acquisition Corp., is a microbiome company. The Company is focused on developing both natural and engineered phage therapies. It develops therapies to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC) and cancer... see more

Recent & Breaking News (NYSEAM:PHGE)

BiomX Inc. Receives Notice of Compliance with NYSE American Continued Listing Standards

GlobeNewswire December 16, 2024

BiomX Announces Third Quarter 2024 Financial Results and Provides Business and Program Updates

GlobeNewswire November 14, 2024

BiomX to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 14, 2024

GlobeNewswire November 12, 2024

BiomX Announces a Mandatory Unit Separation

GlobeNewswire October 15, 2024

BiomX to Provide Latest Update on Positive Phase 1b/2a Clinical Trial Data for BX004 at the North American Cystic Fibrosis Conference

GlobeNewswire September 18, 2024

BiomX to Present at the H.C. Wainwright 26th Annual Global Investment Conference

GlobeNewswire September 4, 2024

BiomX to Present Positive Phase 1b/2a Clinical Trial Data for BX004 at the European Respiratory Society (ERS) Congress 2024

GlobeNewswire September 3, 2024

UPDATE ON UNITS - BiomX Inc. Announces 1-for-10 Reverse Stock Split

GlobeNewswire August 16, 2024

BiomX Reports Second Quarter 2024 Financial Results and Provides Business and Program Updates

GlobeNewswire August 15, 2024

BiomX Inc. Announces 1-for-10 Reverse Stock Split

GlobeNewswire August 15, 2024

BiomX to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 15, 2024

GlobeNewswire August 8, 2024

BiomX Inc. Announces NYSE American Acceptance of Plan to Regain Listing Compliance

GlobeNewswire July 29, 2024

BiomX Inc. Announces Stockholder Approval for Conversion of Outstanding Series X Convertible Preferred Stock to Common Stock

GlobeNewswire July 10, 2024

BiomX Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

GlobeNewswire May 30, 2024

BiomX to Present Phase 1b/2a Clinical Trial Data for BX004 at the 47th European Cystic Fibrosis Conference and at ASM Microbe 2024

GlobeNewswire May 30, 2024

BiomX Reports First Quarter 2024 Financial Results and Provides Business and Program Updates

GlobeNewswire May 21, 2024

BiomX to Host First Quarter 2024 Financial Results Conference Call and Webcast on May 21, 2024

GlobeNewswire May 15, 2024

BiomX to Present Data from Phase 1b/2a Study of BX004 for the Treatment of Cystic Fibrosis Patients with Chronic Pulmonary Infections at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2024)

GlobeNewswire April 23, 2024

BiomX Announces the Appointment of Susan Blum to its Board of Directors

GlobeNewswire April 18, 2024

BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure

GlobeNewswire April 4, 2024